New drug shows sustained benefit at 2 years in rare blood cancer

the ONA take:

Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia, a rare blood cancer.

In addition, 95% of patients receiving the newly approved drug are experiencing progression-free survival 2 years after initiating treatment. When progression did occur, it began at a median of 9.6 months after the start of treatment.

Waldenstrom macroglobulinemia is caused by an abnormality in the B lymphocytes in bone marrow that causes the overproduction of IgM, an immunoglobulin protein that thickens the blood.

It is driven by the MYD88 and CXCR4 genetic mutations. MYD88 mutation triggers abnormal activity of Bruton’s tyrosine kinase. Ibrutinib targets a pathway involving Bruton’s tyrosine kinase protein.

The trial included 63 patients who had received at least one prior treatment. The drug is administered as an oral drug taken daily.

Treatment continued until the disease worsened or unacceptable toxic effects occurred. Response rate in the study refers to the degree of reduction in IgM in the blood.

New drug shows sustained benefit at 2 years in rare blood cancer
Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia.
The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95% of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs